CRisP is a translational research environment at one of the world’s leading medical universities, Karolinska Institutet. Through a cross-disciplinary and collaborative approach, focusing on individualized cancer risk prediction and prevention, we develop strategies that decrease the mortality of breast and prostate cancer.
Find out more about CRisP and how you can join our cause.
Breast cancer is the most common cancer among women in Sweden with almost 8,000 new cases annualy. In Sweden 1,500 women die from breast cancer yearly but there is a remarkable difference between outcomes of localized vs advanced disease.
Prostate cancer is the most common cancer among men in Sweden today and yearly almost 10,000 new cases are diagnosed. Despite the old age of onset, the morbidity and mortality of this cancer is substantial with more than 2,500 deaths annually.We know that cancer mortality can be reduced if cases are detected and treated early, but there is a problem with over-diagnosis and over-treatment. What if we instead could predict the risk for aggressive cancers? Our research focuses on understanding cancer risk and how to design individualized prevention strategies.
Read more about our research.
